LONDON (Alliance News) - Angle PLC on Thursday said its ParsortixTM system was used by the University of Texas MD Anderson Cancer Center to develop a new technique for assessing the metastatic potential of breast cancer.
The stock was trading 5.1% higher in London at 72.00 pence a share.
The liquid biopsy company said the technique, transmembrane receptor dynamics, measures the dynamics of cytoskeletal structure and mechanical properties of live cancer cells held within the microfluidic Parsortix cassette using an optical interrogation technique.
The research states that the transmembrane receptor dynamics approach can serve "as a new biophysical marker to probe the metastatic potential of cancer cells and even to monitor the transition of metastasis".
This offers the potential to differentiate highly invasive cancer cells from non to less-invasive cancer cells allowing more personalised treatment to be offered to the patient, Angle explained.
The researchers also stated that transmembrane receptor dynamics can be easily performed within the Parsortix system.
"We are pleased to see new applications of the system being developed by independent users of Parsortix, all of which add to the body of evidence and generate new commercial opportunities," said Angle Founder & Chief Executive Andrew Newland.
Angle (AGL)